Downregulation of stearoyl-CoA desaturase 1 (SCD-1) promotes resistance to imatinib in chronic myeloid leukemia

dc.authoridSüreyya Bozkurt / 0000-0002-1765-9894en_US
dc.authoridYahya Büyükaşık / 0000-0002-2700-295Xen_US
dc.authorscopusidSüreyya Bozkurt / 55540860700en_US
dc.authorscopusidYahya Büyükaşık / 7004677909en_US
dc.authorwosidSüreyya Bozkurt / EQA-5358-2022en_US
dc.authorwosidYahya Büyükaşık / GCQ-9492-2022en_US
dc.contributor.authorGünes, Buket Altınok
dc.contributor.authorHekmatshoar, Yalda
dc.contributor.authorÖzkan, Tülin
dc.contributor.authorBozkurt, Süreyya
dc.contributor.authorAydos, Oya Sena Erdoğan
dc.contributor.authorBüyükaşık, Yahya
dc.contributor.authorAladağ, Elifcan
dc.contributor.authorAsuman Sunguroğlu
dc.date.accessioned2023-08-31T12:07:20Z
dc.date.available2023-08-31T12:07:20Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümüen_US
dc.description.abstractChronic myeloid leukemia (CML) is a malignant hematopoietic stem cell disease resulting in the fusion of BCR and ABL genes and characterized by the presence of the reciprocal translocation t(9;22)(q34;q11). BCR-ABL, a product of the BCR-ABL fusion gene, is a structurally active tyrosine kinase and plays an important role in CML disease pathogenesis. Imatinib mesylate (IMA) is a strong and selective BCR-ABL tyrosine kinase inhibitor. Although IMA therapy is an effective treatment, patients may develop resistance to IMA therapy over time. This study investigated the possible genetic resistance mechanisms in patients developing resistance to IMA. We did DNA sequencing in order to detect BCR-ABL mutations, which are responsible for IMA resistance. Moreover, we analyzed the mRNA expression levels of genes responsible for apoptosis, such as BCL-2, P53, and other genes (SCD-1, PTEN). In a group of CML patients resistant to IMA, when compared with IMA-sensitive CML patients, a decrease in SCD-1 gene expression levels and an increase in BCL-2 gene expression levels was observed. In this case, the SCD-1 gene was thought to act as a tumor suppressor. The present study aimed to investigate the mechanisms involved in IMA resistance in CML patients and determine new targets that can be beneficial in choosing the effective treatment. Finally, the study suggests that the SCD-1 and BCL-2 genes may be mechanisms responsible for resistance.en_US
dc.identifier.citationGunes, B. A., Hekmatshoar, Y., Ozkan, T., Bozkurt, S., Aydos, O. S., Buyukasik, Y., ... & Sunguroglu, A. (2023). DOWNREGULATION OF STEAROYL-COA DESATURASE 1 (SCD-1) PROMOTES RESISTANCE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA: Downregulation of Scd-1 in Chronic Myeloid Leukemia. Mediterranean Journal of Hematology and Infectious Diseases, 15(1), e2023008-e2023008.en_US
dc.identifier.doi10.4084/MJHID.2023.008en_US
dc.identifier.issn2035-3006en_US
dc.identifier.scopus2-s2.0-85151259021en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttp://dx.doi.org/10.4084/MJHID.2023.008
dc.identifier.urihttps://hdl.handle.net/20.500.12713/3964
dc.identifier.wosWOS:000907654000001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.institutionauthorBozkurt, Süreyya
dc.institutionauthorBüyükaşık, Yahya
dc.language.isoenen_US
dc.publisherMattioli 1885en_US
dc.relation.ispartofMediterranean Journal of Hematology And Infectious Diseasesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCMLen_US
dc.subjectImatinib Resistanceen_US
dc.subjectBCR-ABL Mutationsen_US
dc.subjectSCD-1en_US
dc.titleDownregulation of stearoyl-CoA desaturase 1 (SCD-1) promotes resistance to imatinib in chronic myeloid leukemiaen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
Altinok+Gunes+PDF.pdf
Boyut:
877.52 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: